HighTide Therapeutics is dedicated to the discovery and development of innovative therapeutics for people suffering from chronic liver diseases, gastrointestinal diseases and metabolic disorders with large and unsatisfied market needs.
HighTide Therapeutics today announced that the Company will present at the fifth annual NASH-TAG Conference. The hybrid (in-person/virtual) conference, focused on therapeutic agents for non-alcoholic steatohepatitis (NASH) and liver fibrosis
HighTide Therapeutics today announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright Global Life Sciences Conference March 9-10, 2021.
